Log In
BCIQ
Print this Print this
 

CT200

  Manage Alerts
Collapse Summary General Information
Company Celleron Therapeutics Ltd.
DescriptionCompound that selectively targets cancer cells through reinstated E2F checkpoint pathway
Molecular Target Undisclosed
Mechanism of ActionE2F activator
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat metastatic cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today